Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DNK102
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DNK102 is an investigational allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech. It is engineered to dual-target Claudin 18.2 (CLDN18.2) and Mucin 1 (MUC1), two antigens frequently overexpressed in solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC). By utilizing a dual-recognition CAR construct, EB-DNK102 aims to enhance tumor specificity and overcome antigen escape, a common challenge in single-target cell therapies. As an allogeneic "off-the-shelf" product, it is derived from healthy donor cells, potentially offering logistical advantages over autologous therapies. The therapy is currently being evaluated in Phase 1/2 clinical trials for patients with unresectable or metastatic PDAC, typically following lymphodepleting chemotherapy to facilitate cell expansion and persistence.
- Other names
- EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)
02
Targets
Claudin 18.2MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on EB-DNK102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DNK102.